

# Katherine S Panageas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5550077/publications.pdf>

Version: 2024-02-01

98  
papers

7,549  
citations

94433

37  
h-index

58581

82  
g-index

101  
all docs

101  
docs citations

101  
times ranked

13956  
citing authors

#	ARTICLE	IF	CITATIONS
1	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. <i>Nature</i> , 2017, 545, 60-65.	27.8	1,280
2	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	1.6	892
3	Risk of Arterial Thromboembolism in Patients With Cancer. <i>Journal of the American College of Cardiology</i> , 2017, 70, 926-938.	2.8	465
4	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019, 565, 654-658.	27.8	361
5	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
6	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.0	275
7	R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. <i>Blood</i> , 2015, 125, 1403-1410.	1.4	267
8	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. <i>Cancer Discovery</i> , 2018, 8, 1006-1025.	9.4	248
9	Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. <i>Neuro-Oncology</i> , 2014, 16, 829-840.	1.2	198
10	When You Look Matters: The Effect of Assessment Schedule on Progression-Free Survival. <i>Journal of the National Cancer Institute</i> , 2007, 99, 428-432.	6.3	160
11	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. <i>Blood</i> , 2019, 133, 436-445.	1.4	159
12	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	3.7	154
13	Arterial thromboembolic events preceding the diagnosis of cancer in older persons. <i>Blood</i> , 2019, 133, 781-789.	1.4	127
14	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	7.1	125
15	Non-conventional Inhibitory CD4 <sup>+</sup> Foxp3 <sup>+</sup> PD-1 <sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	16.8	112
16	Trends in survival from primary central nervous system lymphoma, 1975-1999. <i>Cancer</i> , 2005, 104, 2466-2472.	4.1	106
17	Blockade of surface-bound TGF- $\beta$ 2 on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. <i>Science Signaling</i> , 2017, 10, .	3.6	100
18	Evaluation of CD8 <sup>+</sup> T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. <i>International Journal of Cancer</i> , 2000, 87, 391-398.	5.1	98

#	ARTICLE	IF	CITATIONS
19	Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. <i>Clinical Cancer Research</i> , 2016, 22, 4786-4796.	7.0	95
20	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	16.8	93
21	High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. <i>Cancer</i> , 2020, 126, 76-85.	4.1	92
22	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
23	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	6.1	83
24	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	8.5	82
25	Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2017, 19, 1248-1254.	1.2	79
26	Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors. <i>JAMA Oncology</i> , 2021, 7, 720.	7.1	68
27	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	3.7	57
28	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407.	2.9	55
29	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
30	Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma. <i>Neuro-Oncology</i> , 2017, 19, 1532-1541.	1.2	51
31	Initial treatment patterns over time for anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2012, 14, 761-767.	1.2	48
32	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	7.0	48
33	Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation. <i>Journal of Neuro-Oncology</i> , 2019, 144, 553-562.	2.9	48
34	Physician-Driven Variation in Nonrecommended Services Among Older Adults Diagnosed With Cancer. <i>JAMA Internal Medicine</i> , 2016, 176, 1541.	5.1	44
35	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
36	Properties of analysis methods that account for clustering in volume-“outcome studies when the primary predictor is cluster size. <i>Statistics in Medicine</i> , 2007, 26, 2017-2035.	1.6	42

#	ARTICLE	IF	CITATIONS
37	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946.	1.5	41
38	Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies. <i>Cancer</i> , 2021, 127, 2062-2073.	4.1	40
39	Patterns of treatment in older adults with primary central nervous system lymphoma. <i>Cancer</i> , 2007, 110, 1338-1344.	4.1	39
40	Elevated Blood Neutrophil-to-Lymphocyte Ratio: A Readily Available Biomarker Associated with Death due to Disease in High Risk Nonmetastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 1989-1996.	1.5	39
41	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	1.5	39
42	An IRAK1-PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. <i>Nature Cell Biology</i> , 2019, 21, 203-213.	10.3	38
43	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. <i>Neuro-Oncology</i> , 2017, 19, 1380-1390.	1.2	35
44	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 3435-3447.	8.2	33
45	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
46	Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series. <i>Neuro-Oncology</i> , 2020, 22, 979-992.	1.2	31
47	EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 337-345.	2.9	30
48	An optimal two-stage phase II design utilizing complete and partial response information separately. <i>Contemporary Clinical Trials</i> , 2002, 23, 367-379.	1.9	26
49	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 2226-2235.	7.0	25
50	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015, 33, 3454-3458.	1.6	24
51	Durable 5-year local control for resected brain metastases with early adjuvant SRS: the effect of timing on intended-field control. <i>Neuro-Oncology Practice</i> , 2021, 8, 278-289.	1.6	22
52	Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 257-264.	1.2	20
53	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. <i>Melanoma Research</i> , 2020, 30, 71-75.	1.2	20
54	The effect of surgery on radiation necrosis in irradiated brain metastases: extent of resection and long-term clinical and radiographic outcomes. <i>Journal of Neuro-Oncology</i> , 2021, 153, 507-518.	2.9	20

#	ARTICLE	IF	CITATIONS
55	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€“Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547.	5.9	20
56	Clinical trial design for rare cancers: why a less conventional route may be required. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 661-663.	3.1	18
57	A peripheral blood biomarker estimates probability of survival: the neutrophilâ€“lymphocyte ratio in noncancer patients. <i>Biomarkers in Medicine</i> , 2016, 10, 953-957.	1.4	18
58	Prevalence and Safety of Off-Label Use of Chemotherapeutic Agents in Older Patients With Breast Cancer: Estimates From SEER-Medicare Data. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 57-65.	4.9	18
59	A standardization method to adjust for the effect of patient selection in phase II clinical trials. <i>Statistics in Medicine</i> , 2001, 20, 883-892.	1.6	16
60	Variability in Predictions from Online Tools: A Demonstration Using Internet-Based Melanoma Predictors. <i>Annals of Surgical Oncology</i> , 2018, 25, 2172-2177.	1.5	16
61	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	7.0	16
62	Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation. <i>Journal of Neuro-Oncology</i> , 2021, 155, 277-286.	2.9	16
63	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
64	Quantitative assessment of circulating tumor cells in cerebrospinal fluid as a clinical tool to predict survival in leptomeningeal metastases. <i>Journal of Neuro-Oncology</i> , 2022, 157, 81-90.	2.9	16
65	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 419-426.	6.3	15
66	Personalized electro-acupuncture versus auricular-acupuncture comparative effectiveness (PEACE): A protocol of a randomized controlled trial for chronic musculoskeletal pain in cancer survivors. <i>Medicine (United States)</i> , 2020, 99, e20085.	1.0	14
67	Multivariate Prognostic Model for Patients With Thick Cutaneous Melanoma: Importance of Sentinel Lymph Node Status. <i>Annals of Surgical Oncology</i> , 2002, 9, 637-645.	1.5	13
68	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	1.2	12
69	Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1326.	7.1	11
70	Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 761-768.	2.5	11
71	Increased risk of arterial thromboembolism in older men with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 903-910.	2.5	8
72	The unique burden of rare cancer caregiving: caregivers of patients with Erdheimâ€“Chester disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 1406-1417.	1.3	8

#	ARTICLE	IF	CITATIONS
73	Cerebrospinal fluid diversion for leptomeningeal metastasis: palliative, procedural and oncologic outcomes. <i>Journal of Neuro-Oncology</i> , 2021, 154, 301-313.	2.9	8
74	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
75	Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa159.	0.7	7
76	Coping with glioblastoma: prognostic communication and prognostic understanding among patients with recurrent glioblastoma, caregivers, and oncologists. <i>Journal of Neuro-Oncology</i> , 2022, 158, 69-79.	2.9	7
77	Rosaiâ€œDorfmanâ€œDestombes disease of the nervous system: a systematic literature review. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 92.	2.7	6
78	Interval estimation of the common odds ratio from $(2 \times 2)$ tables under cluster sampling. , 1999, 18, 1087-1100.		5
79	Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors. <i>Neuro-Oncology Practice</i> , 2016, 3, 71-76.	1.6	5
80	Assessment of variation in 30-day mortality following cancer surgeries among older adults across US hospitals. <i>Cancer Medicine</i> , 2020, 9, 1648-1660.	2.8	5
81	A Population-Based Study of Treatment and Survival in Older Glioma Patients. <i>JNCI Cancer Spectrum</i> , 0, , .	2.9	4
82	Intra-arterial Melphalan for Neurologic Non-Langerhans Cell Histiocytosis. <i>Neurology</i> , 2021, 96, 1091-1093.	1.1	3
83	Letter to the Editor Regarding â€œNational Trends for Reoperation in Older Patients with Glioblastomaâ€œ. <i>World Neurosurgery</i> , 2018, 117, 466.	1.3	2
84	Assessing whether cancer stage is needed to evaluate measures of hospital surgical performance. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 66-71.	1.8	2
85	Linked Entity Attribute Pair (LEAP): A Harmonization Framework for Data Pooling. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 691-699.	2.1	2
86	Electronic Medical Record Documentation and Provider Burnout. <i>JCO Oncology Practice</i> , 2021, 17, 158-159.	2.9	2
87	Appropriate statistical methods are available to handle biases encountered in blinded, independent, central review (BICR) determined progression-free survival. <i>Journal of Hospital Management and Health Policy</i> , 2019, 3, 8-8.	0.4	1
88	Cancer and Clot. <i>JACC: CardioOncology</i> , 2021, 3, 219-220.	4.0	1
89	Symptoms, Surgical Events, and Length of Stay of Surgical Oncology Outpatients. <i>Journal of Perianesthesia Nursing</i> , 2022, , .	0.7	1
90	Likelihood Modelling: A Statistical Perspective on Gene Expression Data Analysis. , 2005, , 361-379.		0

#	ARTICLE	IF	CITATIONS
91	Response to Weltman and Fleury Malheiros, re Lassman et al.. Neuro-Oncology, 2012, 14, 677-678.	1.2	0
92	Apples and Oranges? Considerations for EHR-Based Analyses Aggregating Data From Interventional Clinical Trials and Point-of-Care Encounters in Oncology. JCO Clinical Cancer Informatics, 2021, 5, 21-23.	2.1	0
93	Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma. Annals of Surgical Oncology, 2021, 28, 9031-9038.	1.5	0
94	ASO Visual Abstract: Assessment of Frailty Can Guide Decision Making for Utilization of Sentinel Lymph Node Biopsy in Patients with Thick Melanoma. Annals of Surgical Oncology, 2021, 28, 470-471.	1.5	0
95	Acupuncture for Cancer Survivorsâ€™Reply. JAMA Oncology, 2021, 7, 1400.	7.1	0
96	Employing competing risks analysis in an aging population where many patients die from other causes. Journal of Geriatric Oncology, 2021, , .	1.0	0
97	Abstract TP72: Pilot Trial of Enoxaparin versus Aspirin in Cancer Patients with Stroke: the TEACH Study. Stroke, 2017, 48, .	2.0	0
98	Melanoma-Specific Clinical Outcomes of Inpatient Immune Checkpoint Blockade Treatment. Oncologist, 0, , .	3.7	0